Market revenue in 2023 | USD 5.9 million |
Market revenue in 2030 | USD 8.8 million |
Growth rate | 5.8% (CAGR from 2023 to 2030) |
Largest segment | Bioavailability & bioequivalence studies |
Fastest growing segment | Bioavailability & Bioequivalence Studies |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Bioavailability & Bioequivalence Studies, Pharmacokinetics, Pharmacodynamics, Other test type |
Key market players worldwide | IQVIA Holdings Inc, Labcorp Holdings Inc, Thermo Fisher Scientific Inc, Pharmaron Beijing Co Ltd Ordinary Shares - Class H, Charles River Laboratories International Inc, Syneos Health, Intertek Group PLC |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell & gene therapy bioanalytical testing services market will help companies and investors design strategic landscapes.
Bioavailability & bioequivalence studies was the largest segment with a revenue share of 35.59% in 2023. Horizon Databook has segmented the Sweden cell & gene therapy bioanalytical testing services market based on bioavailability & bioequivalence studies, pharmacokinetics, pharmacodynamics, other test type covering the revenue growth of each sub-segment from 2018 to 2030.
The Swedish pharmaceutical market is extremely competitive, with both international pharmaceutical corporations and local producers operating in the country. The market is fueled by innovation, with a large number of clinical trials being conducted in Sweden.
The country has a robust infrastructure for R&D, with numerous academic institutions and research centers working with the pharmaceutical sector to encourage innovation & create novel treatments. Overall, the pharmaceutical sector presents potential for both domestic and international companies; nevertheless, managing the complicated regulatory structure is critical to success.
Moreover, increasing activities by key market players such as partnerships, investments, and mergers & acquisitions can be attributed to the growing need for cell and gene therapy bioanalytical testing services in Sweden.
Horizon Databook provides a detailed overview of country-level data and insights on the Sweden cell & gene therapy bioanalytical testing services market , including forecasts for subscribers. This country databook contains high-level insights into Sweden cell & gene therapy bioanalytical testing services market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account